|
|
MabCampath(R) Shown to Be Effective in Treatment of Peripheral T-Cell Lymphomas.
- Article from:
-
PR Newswire Europe
- Article date:
-
December 6, 2004
|
Copyright informationCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, December 6 /PRNewswire/ --
- First-Line Chemoimmunotherapeutic Regimen Constitutes New Approach
Data from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated MabCampath (alemtuzumab) was effective in the first-line treatment of peripheral T-cell non Hodgkin's Lymphoma (NHL).
"Peripheral T-cell lymphomas are often associated with unfavorable clinical outcomes," explained Eckhart Weidmann, M.D., of the Department of Hematology and Oncology of Northwest Hospital, Frankfurt, Germany, "The study shows the effectiveness of MabCampath and combination chemotherapy as a first-line therapy for ...